Synapse - Department of Medicine

Results (39615)

HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)

Meeting Abstract

Harding, J. J.; Macarulla, T.; Pant, S.; Wu, X.; Garfin, P. M.; Okusaka, T.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752

Meeting Abstract

Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Lowy, A. M.; Sohal, D.; Reiss, K. A.; Sanford, N. N.; Allegra, C.; Colby, S.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors

Meeting Abstract

Lakhani, N. J.; Melisi, D.; Subbiah, V.; Ammakkanavar, N. R.; O'Reilly, E. M.; Cassier, P. A.; Wainberg, Z. A.; Duffy, A. G.; Patnaik, A.; Fujiwara, Y.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations

Meeting Abstract

Heinrich, M. C.; Blay, J. V.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

How racialized approaches to opioid use disorder and opioid misuse management hamper pharmacoequity for cancer pain

Editorial

Jones, K. E.; Liou, K. T.; Ashare, R. L.; Worster, B.; Yeager, K. A.; Merlin, J.; Meghani, S. H.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Menin inhibition with revumenib for KMT2A -rearranged relapsed or refractory acute leukemia (AUGMENT-101)

Journal Article

Issa, G. C.; Aldoss, I.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G. N.; Perl, A.; Dickens, D. S.; McMahon, C. M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis

Meeting Abstract

Choo, J.; Saini, J.; Gonzalez-Aguirre, A.; Dahi, P.; Hieronymi, S.; Fernstedt, S.; Tan, K. S.; Adusumilli, P. S.; Ku, G. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma

Meeting Abstract

Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)

Meeting Abstract

Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors

Meeting Abstract

Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A. L.; Garofalo, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save